News & AnalysisBiomedicine

Rare Cancer Successes Spawn ‘Exceptional’ Research Efforts

Science  19 Apr 2013:
Vol. 340, Issue 6130, pp. 263
DOI: 10.1126/science.340.6130.263

You are currently viewing the summary.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Summary

Most experimental cancer drugs that reach clinical trials fail to help enough patients, and the drugs are shelved. But in many trials, there are the exceptions: a rare patient with advanced cancer whose tumors shrink or even disappear for many months or years. This month, the U.S. National Cancer Institute (NCI) announced that it is casting a wide net for such "exceptional responders" in hopes of ferreting out genetic or other molecular peculiarities that may explain why a drug sometimes has dramatic beneficial effects in certain patients. NCI also intends to launch a new kind of clinical trial that will genotype a patient's tumor and match it to a potentially effective drug, including experimental drugs that haven't been approved.